From Name:
From Email:
To Name:
To Email:

Optional Message:

Trial of immune drug in breast cancer points to need for biomarkers

from Forbes

At first glance, results with a powerful immune agent in breast cancer appear negative. In an early-phase clinical trial, only 10 percent of patients with metastatic disease responded to atezolizumab (Tecentriq). Yet for those few women who did respond, the benefit was dramatic. Among 112 women with evaluable, advanced disease, 11 have experienced durable responses lasting at least one year. All of those ("100 percent") who responded at one year remained in remission at two years; so far, the median duration of objective responses is 21 months. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063